The Breast
Volume 19, Issue 1 , Pages 38-43 , February 2010

Worsened oncologic outcomes for women of lower socio-economic status (SES) treated for locally advanced breast cancer (LABC) in Pakistan

  • Zeba Aziz

      Affiliations

    • The Department of Oncology, Jinnah Hospital/Allama Iqbal Medical College, Lahore, Pakistan
    • Corresponding Author InformationCorresponding author. Tel.: +92 302 846 1918; fax: +92 42 584 0963.
    • ,
  • Javaid Iqbal

      Affiliations

    • The Department of Oncology, Jinnah Hospital/Allama Iqbal Medical College, Lahore, Pakistan
    • ,
  • Muhammad Akram

      Affiliations

    • The Department of Oncology, Jinnah Hospital/Allama Iqbal Medical College, Lahore, Pakistan
    • ,
  • Benjamin O. Anderson

      Affiliations

    • The Breast Health Global Initiative, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Received 8 September 2009 ,Accepted 8 October 2009.

References 

  1. Malik IA. Clinico-pathologic features of breast cancer in Pakistan. J Pak Med Assoc. 2002;52(3):101–104
  2. Chopra R. The Indian scene. J Clin Oncol. 2001;19:106s–111s
  3. Schwartsman G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol. 2001;19:118s–124s
  4. Agarwal G, Pradeep PV, Agarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007;31(5):1031–1040
  5. El Saghir NS, Khalid MK, Eid T, El Kinge AR, Charafeddine M, Geara F, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5(4):225
  6. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program Public Use Data Tapes 1973–1998, November 2000 submission. Issued: April 2001.
  7. Seidman H, Gelb SK, Silverberg E, et al. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin. 1987;37:258–290
  8. Malin JL, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States?. J Clin Oncol. 2006;24(4):626–634
  9. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490–496
  10. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing of screening mammography in Medicare Health plans. N Engl J Med. 2008;358:375–383
  11. Aziz Z, Sana S, Akram M. Socioeconomic status and breast cancer survival in Pakistani women. J Pak Med Assoc. 2004;54:448–453
  12. Gajalakhshmi CK, Shanta V, Swaminathan R, et al. A population based survival study on female breast cancer in Madras. India. Br J Cancer. 1997;75:771–7758
  13. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792
  14. Newman LA, Griffith KA, Jatoi I, et al. Meta-analysis of survival in African–American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006;24:1342–1349
  15. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–183
  16. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  17. Smith IC, Heys SD, Hutcheon AW, Miller ID, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456–1466
  18. Buzdar AU. Preoperative chemotherapy treatment of breast cancer – a review. Cancer. 2007;110:2394–2407
  19. Woolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102
  20. Mauri D, Pavlidis N, Ioannidis JP, et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–194
  21. Enui A, Carlson R, El Saghir NS, et al. Guidelines implementation for breast healthcare in low- and middle-income countries. Cancer Supplement. 2008;113(8):2269–2281
  22. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross resistant adjuvant chemotherapy on the basis of pathologic response to neoadjuvant doxorubicin based regimen in women with operable breast cancer: long term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294–2302
  23. Silva Orlando E, Zurrida Stefano, Veronesi Umberto. Breast cancer: a practical guide. 3rd ed.. Elsevier Science; 2005;
  24. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitexal followed by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor-2 positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228–233
  25. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer. 2007;110:1195–1200
  26. Parkin DM, Bray F, Ferlay J, Pisani P. Global statistics. CA Cancer J Clin. 2005;55:74–108
  27. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401
  28. Catliotti L, De Wolf C, Holland R, et al. EUSOMA. Guide-lines on the standards for the training of specialized health professionals dealing breast cancer. Eur J Cancer. 2007;43:660–675
  29. Thorat MA, Rangole A, Nadkarne MS, et al. Revision surgery for breast cancer. a single-institution experience. Cancer Suppl. 2008;113(8):2347–2352
  30. Velasco ED, Martins CA, Vidal E, et al. Hospital infections at an oncological hospital. Rev Paul Med. 1990;108(2):61–70
  31. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483
  32. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224–4237
  33. Tatsuzaki H, Levin CV. Quantitative status of resources for radiation therapy in Asia and Pacific region. Radiother Oncology. 2000;60(1):81–89
  34. Ward E, et al. ER/PR-negative breast cancer linked to race and socioeconomic status. AACR Seventh Annual International Conference on Frontiers in Cancer Prevention Research. 2008;Abstr B122
  35. Kuerer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor down staging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998;5(8):673–680
  36. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al. Co-morbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294(14):1765–1772
  37. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Orthod. 2005;23:6639–6646
  38. Carey LA, Perou CM, Chad A, et al. Race, breast cancer subtypes and survival in the Breast Cancer Carolina Study. JAMA. 2006;295(21):2492–2502
  39. Kaufman M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrazole initiated after treatment with tamoxifen compared with continued tamoxifen. J Clin Oncol. 2007;25:2664–2670
  40. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin based and docetexal chemotherapy for node-positive breast cancer patients: the FNLCC PACS 01 trial. J Clin Oncol. 2006;24:5664–5671
  41. Smith I, Procter M, Gelber , et al. 2-Year follow-up of trantuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized trial. Lancet. 2007;369:29–36
  42. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N 9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract). ASCO Annual Meeting Proceedings J Clin Oncol. 2007;25:18S;Abstract 512
  43. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analysis from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20–37
  44. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen receptor status and outcomes of modern chemotherapy for patients with node positive breast cancer. JAMA. 2006;295:1658–1667
  45. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastasis after pre-operative chemotherapy for locally advanced breast cancer. Arch Surg. 1989;124:21–25
  46. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434
  47. Aziz Z, Iqbal J, Akram . Effect of social class disparities on disease stage, quality of treatment and survival outcomes in breast cancer patients from developing countries. Breast J. 2008;14(4):372–375
  48. Executive summary of the national cancer control programs: policies and managerial guidelines. Geneva: World health Organization; 2002;p. 1–24

PII: S0960-9776(09)00121-0

doi: 10.1016/j.breast.2009.10.005

The Breast
Volume 19, Issue 1 , Pages 38-43 , February 2010

Article Tools

* Image Usage & Resolution